Emergent Biosolutions (NYSE:EBS) Posts Earnings Results, Beats Expectations By $0.46 EPS

Emergent Biosolutions (NYSE:EBS) released its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.46, FiscalAI reports. The business had revenue of $156.10 million during the quarter, compared to the consensus estimate of $160.50 million. Emergent Biosolutions had a return on equity of 15.86% and a net margin of 7.08%.

Here are the key takeaways from Emergent Biosolutions’ conference call:

• Emergent reported Q1 revenue of $156 million (above the high end of guidance) and an Adjusted EBITDA of $36 million with a 23% margin, while cash and liquidity improved to $160M and $260M respectively and net debt fell ~22% year‑over‑year.
• The April 2026 debt refinancing extended maturities (out to 2031), lowered interest costs, added a $75M delayed‑draw term loan and a $50M revolver, which management says enhances liquidity and financial flexibility for growth.
• Management emphasized growth levers including international MCM expansion (internationals were ~37% of MCM revenue in Q1), new NARCAN line extensions (carrying case and multi‑pack), strategic manufacturing partnerships (Substipharm, SAB) and continued business‑development/acquisition activity.
• Emergent expects a $50.4 million cash outflow in Q2 as an accrued acquisition obligation to Ridgeback related to the Ebanga/BARDA contract, which management has recorded as a current liability.

Emergent Biosolutions Stock Up 3.9%

Shares of NYSE:EBS traded up $0.32 during midday trading on Thursday, hitting $8.31. 815,393 shares of the company’s stock traded hands, compared to its average volume of 561,464. The firm’s fifty day moving average price is $8.54 and its two-hundred day moving average price is $10.29. The company has a debt-to-equity ratio of 1.09, a quick ratio of 2.41 and a current ratio of 5.01. Emergent Biosolutions has a twelve month low of $4.71 and a twelve month high of $14.06. The company has a market cap of $428.87 million, a PE ratio of 9.89 and a beta of 2.35.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Millennium Management LLC boosted its position in shares of Emergent Biosolutions by 68.9% in the first quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock worth $12,162,000 after buying an additional 1,020,582 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Emergent Biosolutions by 12.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after buying an additional 121,583 shares during the period. Legal & General Group Plc acquired a new position in Emergent Biosolutions during the 2nd quarter worth approximately $31,000. Rhumbline Advisers lifted its position in Emergent Biosolutions by 862.4% during the 2nd quarter. Rhumbline Advisers now owns 84,025 shares of the biopharmaceutical company’s stock worth $536,000 after acquiring an additional 75,294 shares in the last quarter. Finally, Jump Financial LLC purchased a new position in Emergent Biosolutions in the 2nd quarter worth approximately $352,000. 78.40% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have issued reports on EBS. Wall Street Zen downgraded Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. HC Wainwright cut their price objective on Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a report on Monday, March 9th. Finally, Weiss Ratings cut Emergent Biosolutions from a “sell (d+)” rating to a “sell (d)” rating in a report on Monday. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $12.00.

Emergent Biosolutions Company Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.